These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 16172225)
21. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Bremnes Y; Ursin G; Bjurstam N; Lund E; Gram IT Int J Cancer; 2007 Feb; 120(4):880-4. PubMed ID: 17131324 [TBL] [Abstract][Full Text] [Related]
22. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762 [TBL] [Abstract][Full Text] [Related]
23. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Olsen A; Christensen J; Knudsen KE; Johnsen NF; Overvad K; Tjønneland A Breast Cancer Res Treat; 2011 Aug; 128(3):883-9. PubMed ID: 21340481 [TBL] [Abstract][Full Text] [Related]
24. Intake of whole grains and vegetables determines the plasma enterolactone concentration of Danish women. Johnsen NF; Hausner H; Olsen A; Tetens I; Christensen J; Knudsen KE; Overvad K; Tjønneland A J Nutr; 2004 Oct; 134(10):2691-7. PubMed ID: 15465768 [TBL] [Abstract][Full Text] [Related]
25. Validation of FFQ-based assessment of dietary lignans compared with serum enterolactone in Swedish women. Lin Y; Wolk A; Håkansson N; Peñalvo JL; Lagergren J; Adlercreutz H; Lu Y Br J Nutr; 2013 May; 109(10):1873-80. PubMed ID: 23006454 [TBL] [Abstract][Full Text] [Related]
26. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Frankenfeld CL; McTiernan A; Aiello EJ; Thomas WK; LaCroix K; Schramm J; Schwartz SM; Holt VL; Lampe JW Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1156-62. PubMed ID: 15247126 [TBL] [Abstract][Full Text] [Related]
27. Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Stattin P; Bylund A; Biessy C; Kaaks R; Hallmans G; Adlercreutz H Cancer Causes Control; 2004 Dec; 15(10):1095-102. PubMed ID: 15801493 [TBL] [Abstract][Full Text] [Related]
28. Plasma enterolactone and incidence of endometrial cancer in a case-cohort study of Danish women. Aarestrup J; Kyrø C; Knudsen KE; Weiderpass E; Christensen J; Kristensen M; Würtz AM; Johnsen NF; Overvad K; Tjønneland A; Olsen A Br J Nutr; 2013 Jun; 109(12):2269-75. PubMed ID: 23114205 [TBL] [Abstract][Full Text] [Related]
29. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers. Jaskulski S; Jung AY; Behrens S; Johnson T; Kaaks R; Thöne K; Flesch-Janys D; Sookthai D; Chang-Claude J Int J Cancer; 2018 Dec; 143(11):2698-2708. PubMed ID: 29974464 [TBL] [Abstract][Full Text] [Related]
31. Prenatal and perinatal correlates of adult mammographic breast density. Cerhan JR; Sellers TA; Janney CA; Pankratz VS; Brandt KR; Vachon CM Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1502-8. PubMed ID: 15941963 [TBL] [Abstract][Full Text] [Related]
32. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558 [TBL] [Abstract][Full Text] [Related]
33. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Johansson H; Gandini S; Bonanni B; Mariette F; Guerrieri-Gonzaga A; Serrano D; Cassano E; Ramazzotto F; Baglietto L; Sandri MT; Decensi A Breast Cancer Res Treat; 2008 Mar; 108(1):57-67. PubMed ID: 17468953 [TBL] [Abstract][Full Text] [Related]
34. Physical activity, mammographic density, and age-related lobular involution among premenopausal and postmenopausal women. Hanna M; Dumas I; Jacob S; Têtu B; Diorio C Menopause; 2015 Sep; 22(9):964-75. PubMed ID: 25710783 [TBL] [Abstract][Full Text] [Related]
35. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Vanharanta M; Voutilainen S; Rissanen TH; Adlercreutz H; Salonen JT Arch Intern Med; 2003 May; 163(9):1099-104. PubMed ID: 12742810 [TBL] [Abstract][Full Text] [Related]
36. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283 [TBL] [Abstract][Full Text] [Related]
37. Urinary phytoestrogens and postmenopausal breast cancer risk. den Tonkelaar I; Keinan-Boker L; Veer PV; Arts CJ; Adlercreutz H; Thijssen JH; Peeters PH Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):223-8. PubMed ID: 11303591 [TBL] [Abstract][Full Text] [Related]
38. Impact of a lignan-rich diet on adiposity and insulin sensitivity in post-menopausal women. Morisset AS; Lemieux S; Veilleux A; Bergeron J; John Weisnagel S; Tchernof A Br J Nutr; 2009 Jul; 102(2):195-200. PubMed ID: 19586570 [TBL] [Abstract][Full Text] [Related]
39. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Guglielmini P; Rubagotti A; Boccardo F Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938 [TBL] [Abstract][Full Text] [Related]
40. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Hedelin M; Klint A; Chang ET; Bellocco R; Johansson JE; Andersson SO; Heinonen SM; Adlercreutz H; Adami HO; Grönberg H; Bälter KA Cancer Causes Control; 2006 Mar; 17(2):169-80. PubMed ID: 16425095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]